Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Alice Shaw, MD, PhD
CONTACT
Lead
Dana-Farber Cancer Institute
With
This study evaluates a treatment regimen combining TNG462 and lorlatinib, both administered once daily per the consent study plan. Baseline assessments are performed before registration, with protocol-specified on-treatment visits during Cycle 1, Cycle 2, and subsequent cycles. Scheduled evaluations include physical examinations, vital signs, weight, performance status, laboratory testing, ECGs, adverse event review, and tumor measurements. Tumor imaging is repeated every 2 cycles for the first 6 months, then every 3 cycles thereafter. The consent form also describes optional tumor biopsies and optional plasma/serum collections for research. For the Phase I portion, the protocol states that a BF-BOIN dose-escalation and backfilling design will be used, with no formal stratification factors applied to dose-escalation decisions.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
